3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
Creutzig
U
U
Körholz
D
D
Niemeyer
C M
CM
Kabisch
K
K
Graf
N
N
Reiter
A
A
Scheel-Walter
H
H
Bender-Götze
C
C
Behnisch
W
W
Hermann
J
J
Mann
G
G
Ritter
J
J
Zimmermann
M
M
D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005858:Germany; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage* / Q000009:adverse effects; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D010865:Pilot Projects; D012074:Remission Induction; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D015255:Idarubicin